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Abstract: Background. Hemangiopericytoma (HPC) of the
head and neck is a rare neoplasm whose biologic behavior is
difficult to predict by means of conventional histologic param-
eters.
Methods. H & E–stained sections from 12 cases of HPC were
reviewed. Proliferation index was assessed using an immunoper-
oxidase stain for MIB-1 (Ki-67).
Results. The study group consisted of 4 adult men, 5 adult
women, and 1 infant male. Necrosis, hypercellularity, and pleo-
morphism were found in 1, 5, and 6 case(s), respectively. The
mitotic index per 10 high power fields varied from 0-1 to 15.
Proliferation indices using MIB-1 ranged from 2.6% to 52.5%.
Clinical follow-up revealed 3 cases with recurrence all possess-
ing proliferation indices of approximately 10%.
Conclusions. Standard histomorphologic features may be in-
adequate predictors of clinical outcome. A proliferation index of
10% or greater may indicate a more aggressive subset of HPC of
the head and neck. © 2001 John Wiley & Sons, Inc. Head Neck
23: 492–496, 2001.
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Hemangiopericytoma (HPC), first described by
Stout and Murray1 in 1942, is an uncommon vas-
cular tumor that arises from pericytes. Although
the precise function of pericytes is unknown,
these ovoid cells are intimately associated around
capillaries and possess structural similarity to
smooth muscle cells and fibroblasts, suggesting a
contractile and supportive role.2
Although these tumors represent only a small
fraction of all head and neck tumors, approxi-
mately one fifth of all HPCs are seen at this
site.3,4 HPCs more commonly arise in the lower
extremity and pelvic retroperitoneum.5
The architectural pattern of HPC can be seen
in other mesenchymal neoplasms. The diagnosis
of HPC is one of exclusion and relies on the pres-
ence of characteristic histologic features. How-
ever, difficulties exist in attempting to predict
biologic behavior based on conventional histo-
pathologic parameters. The purpose of this study
is to assess the histologic features and to evaluate
the prognostic significance of the proliferation in-
dex in HPC of the head and neck.
MATERIALS AND METHODS
During the years of 1989 to 1999, 12 cases (10
patients) of primary or recurrent HPC of the head
and neck were retrieved from the surgical pathol-
ogy files of the University of Michigan. The avail-
able clinical data were reviewed, and additional
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clinical information was obtained by contacting
primary physicians. In this study group, there
were 4 adult men (ages 25–83), 5 adult women
(ages 45–55), and 1 infant male (2 months). Sites
of involvement included the orbit (n 4 4), maxil-
lary sinus (n 4 2), nasal cavity (n 4 2), maxilla
(n 4 2) (Fig. 1), mandible (n 4 1), and temporal
region (n 4 1). All patients were treated by sur-
gical excision, and 1 patient received radio-
therapy after 2 recurrences. The primary resec-
tion was reviewed in 9 cases. One patient’s
material was a recurrence 20 years after treat-
ment of a maxillary sinus HPC.
H & E–stained sections from all cases were
reviewed to confirm the diagnosis and to assess
the following histologic features: pleomorphism,
hypercellularity, necrosis, and the number of mi-
totic figures per 30 high power fields (hpf).
The proliferation index was determined as a
percentage of cells, from a minimum of a 1000
counted, with positively staining nuclei. Forma-
lin-fixed, paraffin-embedded tissue sections were
stained immunohistochemically according to
manufacturer’s recommendations with MIB-1, a
monoclonal antibody to a known recombinant
peptide corresponding to the Ki-67 cDNA frag-
ment (Immunotech, Marseilles, France, dilution:
1/25). The sections were pretreated with micro-
wave antigen retrieval followed by staining with a
standard avidin-biotinyl peroxidase complex
method using an automated immunostainer
(Ventana Medical Systems, Inc., Tucson, AZ). Im-
munoperoxidase staining for smooth muscle actin
and S100 was also used on selected cases to ex-
clude the possibility of other mesenchymal neo-
plasms.
RESULTS
The histopathologic features and clinical informa-
tion of the 12 cases are summarized in Table 1.
All cases microscopically consisted of branching
vascular spaces with oval or spindle-shaped peri-
cytes arranged in a random pattern filling the
areas between the vessels (Fig. 2). Pleomorphism
Table 1. Clinical and histologic features of hemangiopericytomas of the head and neck.
Age(y)/
gender Site Pleomorphism Necrosis
Increased
cellularity Mitosis* P/R† PI‡
Follow-
up (mo) Status§
55/F Orbit No No No 0–1 P 3.9 105 U
50/F Orbit Yes No No 15 P 52.5 27 NED
30/M Orbit No No Yes 0–1 P 9.4 15 NED
35/M Nasal cavity No No Yes 0 P 4.5 42 NED
49/F Nasal cavity Yes No No 0 P 4.0 17 NED
48/F Maxillary sinus No No No 0–1 P 3.5 130 U
27/M Temporal bone Yes No Yes 0–1 P 2.6 27 NED
2 mo/M Mandible Yes No Yes 4 P 19.6 83 NED
34/F Maxillary sinus No No No 0–1 P 3.6 136 MR
42/F Maxilla Yes Yes No 0–1 R 10.2 34 MR
44/F Maxilla Yes No Yes 0–1 R 16.8 13 MR
83/M Orbit No No No 0–1 R 9.8 10 MR
*Mitoses/10 high power fields with 30 fields counted.
†Lesion studied: primary (P) or recurrence (R).
‡Proliferation index percentage counting 1000 cells for MIB-1 nuclear positivity.
§MR = multiple recurrences; NED = no evidence of disease; U = unknown.
FIGURE 1. CT scan of a right nasal hemangiopericytoma infil-
trating the nasal sinuses.
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and increased cellularity were observed in 6 and 5
cases, respectively, with 3 cases exhibiting both
features. Focal necrosis was found in only 1 case.
This patient subsequently had two recurrences,
the first of which was pleomorphic with a low mi-
totic index, and the second was pleomorphic and
hypercellular but lacked necrosis or an increased
mitotic rate.
An increased mitotic index was observed in
only 2 cases compared with the 0-1 mitoses/10 hpf
as seen in all other cases. The single congenital
case involved a 2-month-old infant with more
than 20 cutaneous lesions that spontaneously re-
solved after several months. This resection speci-
men was pleomorphic, hypercellular, and pos-
sessed an increased mitotic rate (4/10 hpf) and
proliferation index (19.6%). Similarly, an orbital
lesion was the most mitotically active (15/10 hpf)
and the most proliferative at 52.5% (Fig. 3).
The proliferation index ranged from 2.6% to
52.5%. One case exhibiting both pleomorphism
and increased cellularity possessed the lowest
proliferation index at 2.6% (Fig. 4). The prolifera-
tion index of 6 cases, including the congenital
case, was approximately 10%. The 3 recurrent le-
sions had proliferation indices ranging from 9.8%
to 16.8% (Fig. 5). In addition, two orbital lesions,
with proliferation indices of 9.4% and 52.5%, have
not recurred after 15 and 27 months of follow-up.
DISCUSSION
Numerous studies have described the clinical and
pathologic features of HPC since its first descrip-
tion in 1942.1 The lesion predominates in the ret-
roperitoneum and lower extremities, with the
head and neck as the third most common loca-
tion.3,6,7 HPC can occur in any age group, but the
FIGURE 2. Branching vascular spaces with surrounding peri-
cytes (H & E, original magnification ×10).
FIGURE 3. Positive nuclear staining for MIB-1 in an orbital lesion,
proliferation index = 52.5% (H & E, original magnification × 40).
FIGURE 4. Positive nuclear staining for MIB-1 in an HPC of the
temporal region, proliferation index = 2.6% (H & E, original mag-
nification × 40).
FIGURE 5. Positive nuclear staining for MIB-1 in a recurrent max-
illary HPC, proliferation index = 10.2% (H & E, original magnifi-
cation × 40).
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highest incidence is in the fifth and sixth decades.
There is no sex predilection.2,3 An expanding
mass that may be associated with pain is the com-
mon clinical presentation.3,8 Surgical excision is
the preferred treatment, but local recurrence and
metastasis can subsequently occur up to 50% of
cases.2,4,9
Microscopically, HPC is characterized by a
proliferation of pericytes in between variably
sized, branching, thin-walled vascular channels.
The pericytes have uniform, ovoid nuclei with
indistinct cell borders and are located outside
the reticulin sheath of the endothelium. Micro-
scopic features ascribed prognostic value in-
clude increased cellularity, anaplasia, necrosis,
hemorrhage, and prominent mitotic activity.3
Enzinger and Smith reported 8 of 16 HPCs
that metastasized and had more than 4 mitoses
per 10 hpf, whereas 46 of 66 cases without recur-
rence or metastasis had no mitotic figures in 30
hpf. The remaining 8 metastatic cases were not as
mitotically active but were hypercellular, ne-
crotic, or hemorrhagic.3 Similarly, McMaster, et
al2 showed a general trend toward malignancy
with hypercellular, mitotically active HPCs
stratified into low, intermediate, and high-grade
neoplasms.
Despite these features, it is difficult to predict
the clinical outcome of HPC, including those in
the head and neck. Although a trend toward ma-
lignancy is observed in intermediate and high-
grade lesions, one study has shown that even low-
grade orbital HPCs have the potential for
recurrence or metastasis.10
HPC of the head and neck can occur at any
age. The more common sites specific in this region
include the scalp, face, neck, oral cavity, nasal
cavity, paranasal sinuses, and orbit.4,8,11 Treat-
ment is primarily surgical, although some reports
advocate the use of radiation therapy in those pa-
tients with a high-grade lesion or incomplete re-
sections.12,13
HPCs of the head and neck are believed to
behave more favorably compared with their coun-
terparts in other anatomic sites.4,8,14 Walike and
Bailey8 reported a 44% local recurrence rate, but
only 4 of 43 patients demonstrated metastasis.
Although no apparent explanation for this less
malignant behavior is evident, data from other
reports show similar rates of recurrence and me-
tastasis.4 Our data, although small in number,
seem to support this observation with a recur-
rence rate of 25% and no mortalities.
Few reports are available on the immunohis-
tochemical study of proliferation markers in HPC,
and none specifically address their application to
these tumors in the head and neck region. One
report describes 7 of 9 recurrent or metastatic
HPCs with proliferation rates of 15% or greater
using an antibody to MIB-1. However, none of
these cases originated in the head and neck.15 Yu
et al16 studied 25 HPCs of unspecified sites using
a monoclonal antibody to proliferating cell
nuclear antigen (PCNA). Patients with a PCNA
staining of at least 14% experienced local or meta-
static disease or have died, but those with stain-
ing less than 14% were all alive. As shown in
Table 1, three recurrent cases had MIB-1 prolif-
erative indices of 9.8%, 10.2%, and 16.8%. In con-
trast, most primary lesions possessed prolifera-
tion rates ranging from 2.6% to 4.5%. Although
the number of cases precludes statistical analysis,
a proliferation index of 10% may serve as a useful
predictor of a more aggressive biologic behavior.
Of the 3 primary lesions with proliferation indices
greater than 4.5%, 2 have only 15 and 27 months
of clinical follow-up, and the third is an infantile
HPC.
Infantile or congenital HPC differs clinically
and pathologically from the adult form. Congeni-
tal HPCs are predominantly subcutaneous head
and neck lesions that display an indolent behav-
ior despite worrisome histologic features such as
extensive necrosis and hemorrhage, hypercellu-
larity, and increased mitotic figures.17 Multiple
congenital HPCs of the head and neck have been
reported18 similar to our infantile case with more
than 20 lesions that eventually regressed. This
case exhibited hypercellularity, increased mitotic
figures, and a proliferation rate of 19.6% in keep-
ing with a tendency toward higher proliferation
indices in congenital HPCs.16
In summary, HPC is an uncommon vascular
tumor in which the biologic behavior is difficult to
predict when based solely on conventional histo-
logic parameters. Features suggestive of a high-
grade lesion with an increased risk for subse-
quent recurrence or metastasis include increased
cellularity, necrosis, hemorrhage, and increased
mitotic activity. These features can be supple-
mented by determining the proliferation index us-
ing immunohistochemical techniques. A prolif-
eration index of 10% or greater, as measured with
MIB-1, may be indicative of a more aggressive
subset of these rare neoplasms.
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